People: Flamel Technologies SA (FLML.OQ)

FLML.OQ on NASDAQ Stock Exchange Global Market

15.00USD
29 Aug 2014
Price Change (% chg)

$0.30 (+2.04%)
Prev Close
$14.70
Open
$14.72
Day's High
$15.06
Day's Low
$14.65
Volume
16,996
Avg. Vol
53,969
52-wk High
$15.95
52-wk Low
$5.30

Search Stocks

Summary

Name Age Since Current Position

Stephen Willard

2012 Non-Executive Chairman of the Board

Michael Anderson

2012 Chief Executive Officer, Director

Sian Crouzet

2008 Principal Financial Officer

Rafael Jorda

2005 Chief Operating Officer, Executive Vice President

Steven Lisi

2012 Senior Vice President - Business and Corporate Development

Gregg Stetsko

2013 Vice President - Research & Development

Catherine Castan

Director - Micropump Platform (Oral Drugs) and Intellectual Property

Christian Kalita

2005 Pharmacist and Director - Quality Assurance and Regulatory Affairs

Elie Vannier

63 2012 Director

Catherine Brechignac

2011 Independent Director

Guillaume Cerutti

2011 Independent Director

Francis Fildes

2008 Independent Director

Craig Stapleton

69 2011 Independent Director

Biographies

Name Description

Stephen Willard

Mr. Stephen H. Willard has been appointed as Non-Executive Chairman of the Board of Flamel Technologies S.A., effective June 22, 2012. He is Director since 2001. Prior to being asked to serve as CEO by the Board of Directors in June of 2005, Mr. Willard was the Company’s Chief Financial Officer and General Counsel. Prior to joining the Company in August 2000, Mr. Willard was Vice President of Biovail Corporation (now Valeant Pharmaceuticals International, Inc.; NYSE/TSX: VRX). He previously served as Associate Director of Resolutions of the Federal Deposit Insurance Corporation ("FDIC") of the USA. Mr. Willard worked also as an investment banker at Credit Suisse First Boston and as an attorney with Gibson, Dunn & Crutcher LLP and Shearman & Sterling LLP. He is a member of the Board of Directors of E-Trade Financial Corporation (NASDAQ: ETFC) since April 2005. Mr. Willard is a Juris Doctorate of Yale Law School (USA) and received a Bachelor of Arts degree from Williams College (USA).

Michael Anderson

Mr. Michael S. Anderson serves as Chief Executive Officer, Director of Flamel Technologies S.A. He has also served as Chief Executive Officer of Éclat Pharmaceuticals LLC since its creation in November 2010. Previously Mr. Anderson worked for KV Pharmaceuticals as President and CEO of its generic business, ETHEX Corporation and President and CEO of Ther-Rx Corporation, a leader in women’s healthcare. Mr. Anderson also has worked for Schein Pharmaceuticals and started his career at A.H Robins.

Sian Crouzet

Mrs. Sian Crouzet is Principal Financial Officer of Flamel Technologies SA., since March 3, 2008. She previously worked as Financial Controller France for McCormick & Company Inc. Mrs. Crouzet also worked five years as an external auditor with Ernst and Young (France and UK). She is a UK Chartered Accountant and a graduate of Bradford University (UK).

Rafael Jorda

Mr. Rafael Jorda is Chief Operating Officer, Executive Vice President of Flamel Technologies SA. He joined the Company in early 1991. Previously, Mr. Jorda had worked 14 years as a research and development scientist on controlled-released and biopolymers at Rhone-Poulenc. He specializes in chemical engineering and in the structure-property relationships of materials. Mr Jorda is a graduate of “Ecole Nationale Supérieure de Chimie de Lyon” (France).

Steven Lisi

Mr. Steven Lisi has been appointed as Senior Vice President - Business and Corporate Development of Flamel Technologies SA., effective June 25, 2012. Previously, he served as partner at Deerfield Management, a leading global healthcare focused hedge fund, between 2007 and 2012. Prior to that, he was founder and managing member/portfolio manager at Panacea Asset Management LLC (New York) between 2005 and 2007, and healthcare portfolio manager at Millenium Partners (New York) between 2002 and 2005. Between 1994 and 2002, he served as analyst in several companies. Mr. Lisi is a graduate of Pepperdine University (Malibu, California).

Gregg Stetsko

Dr. Gregg Stetsko is Vice President - Research and Development of of Flamel Technologies SA in February 2013. Dr. Stetsko has over 30 years of experience in the pharmaceutical business, with roles of increasing responsibility at Sandoz, Sterling Winthrop, Ligand Pharmaceutical, and Amylin, where he was Vice President of Operations and Global Leader for the Amylin-Lilly Exenatide Alliance. More recently, he was Chief Scientific Officer for Eagle Pharmaceuticals and a Principal at Tahoe Consulting. Dr. Stetsko earned a B.S. degree in Pharmacy from the University of Rhode Island and a Ph.D. in Industrial and Physical Pharmacy from Purdue University.

Catherine Castan

Mrs. Catherine Castan is Director - Micropump Platform (Oral Drugs) and Intellectual Property of Flamel Technologies SA. She joined the Company in 1992 after having spent four years at Sanofi Recherche. Mrs. Castan is a graduate of “Ecole Nationale Supérieure de Chimie de Montpellier” and has a Ph.D. in polymer chemistry, applied in drug delivery.

Christian Kalita

Mr. Christian Kalita is Pharmacist and Director - Quality Assurance and Regulatory Affairs of Flamel Technologies SA., since 2005. He worked previously at Skye Pharma as Director of Quality for Europe. Mr. Kalita also worked at Merck Lipha and Merck generics for 10 years in different roles as Chief Pharmacist, Head of Quality Control Management and Head of Industrial Affairs.

Elie Vannier

Mr. Elie Vannier serves as Director of Flamel Technologies S.A. He resigned as Non-Executive Independent Chairman of the Board of the Company, effective June 22, 2012. He is the former Group Managing Director of WALLY, former Chief Operating Officer of GrandVision SA, and a current Director of Ingénico, Famar, Conbipel and Pharmacie Principale.

Catherine Brechignac

Dr. Catherine Brechignac is Independent Director of Flamel Technologies SA. She graduated and received her PhD in Physics from the Ecole Normale Supérieure. She is a member and the "Secrétaire Perpétuel" of the French National Academy of Sciences, a member of the French National Academy of Technologies, a member of the American Academy of Arts & Sciences, a member of the Royal Belgium Academy of Sciences, and also serves as the French Ambassador for science, technology and innovation. In addition, Dr Bréchignac is a former Chairperson of the National Center for Scientific Research (CNRS); she served as the first Chairperson of the "Haut Conseil des Biotechnologies" (2009-2011); and she was until recently (2008-2011) the Chairperson of the International Council for Science. Dr. Bréchignac has served as a board member of Renault SA, and was a Professor at the Georgia Institute of Technology, Member of the International Union of Pure and Applied Physics and Member of the European Physical Society. She has been awarded the French Légion d'Honneur and has received honorary doctorates from the Ecole Polytechnique Fédérale in Lausanne, the Georgia Tech Institute, and the Freie Universität Berlin. She was awarded, among numerous prizes, the prize of the Académie des Sciences in 1991 for her ground-breaking research.

Guillaume Cerutti

Mr. Guillaume Cerutti is Independent Director of Flamel Technologies SA. Mr. Cerutti is the Chairman and CEO of Sothebys France. He graduated from the Ecole Nationale d'Administration (ENA) in 1991 and began his career as a civil servant at the Ministry of Finance and the Economy where he worked as a member of the Inspection Générale des Finances. He was the head of the "Direction Générale de la Concurrence et de la Répression des Fraudes" (the French administration charged with enforcing all anti-trust and fraud related issues). He was the Managing Director of the Centre Georges Pompidou between 1996 and 2001. Between 2002 and 2004 he served as chief of staff of France's Minister for Culture and Media, and played a decisive role in the preparation of the laws that reformed corporate sponsorship in France. He currently serves as a director of Ingenico SA, and chairman of the Institut de Financement du Cinéma et des Industries Culturelles (IFCIC), a financial company which offers guarantees and loans in the cultural sector in France.

Francis Fildes

Dr. Francis J.T Fildes, Ph.D., is Independent Director of Flamel Technologies SA., since 2008. He is the former Senior Vice President: Head of Global Development for AstraZeneca, PLC, former Director of ProStrakan Pharmaceuticals PLC and a current Director of Fildes Partners Ltd and a Fellow of the Royal Society of Medicine and the Royal Society of Chemistry.

Craig Stapleton

The Honorable, Ambassador, Craig R. Stapleton is Independent Director of Flamel Technologies SA. He served the United States as Ambassador to France from 2005 until 2009 after having served as the United States Ambassador to Prague. Ambassador Stapleton served as President of Marsh and McLennan Real Estate Advisors of New York from 1982 until 2001. He has served on the board of directors for several companies including Allegheny Properties, Metro PCS, TB Woods and Winston Partners. He was a part owner of the Texas Rangers baseball team from 1989-1998 and is currently a part owner of the St. Louis Cardinals. Ambassador Stapleton is currently serving as a Trustee of the George W. Bush Library and Foundation, the 9/11 Memorial Foundation, the de Tocqueville/United Way Foundation, CERGE (the Center for Economic Research and Graduate Education), and the Association François-Xavier Bagnoud. He has served on the Visiting Committee for Harvard College and the Committee on University Resources. Ambassador Stapleton is President of the Vaclav Havel Foundation in the United States. He currently serves as a Senior Advisor to Stone Point Capital and is the lead director of Abercrombie and Fitch. He received his B.A. (magna cum laude) from Harvard University and his M.B.A. from Harvard Business School.
Search Stocks